Vice President, Development Sciences (Clinical Pharmacology & Nonclinical)
About this role
Employer-provided description, formatted for easier reading.
Lycia Therapeutics is a biotechnology company using its proprietary lysosomal targeting chimera (LYTAC) platform to discover and develop best-in-class therapeutics that degrade extracellular and membrane-bound proteins. These proteins drive a wide range of difficult-to-treat diseases, including autoimmune and inflammatory conditions.
Lycia was established in 2019 in collaboration with academic founder and Nobel Laureate Carolyn Bertozzi, Ph. D. , professor of chemistry and HHMI investigator at Stanford University.
In June, 2026, Lycia Therapeutics completed a $75 million Series D financing to advance its pipeline of LYTAC extracellular protein degraders into the clinic. Lycia is headquartered in South San Francisco.
Visit https://lyciatx. com/ for more information.
Position Summary Highly motivated, creative scientific leader to advance our pipeline of LYTAC degraders and help establish Lycia as the industry leader in endosomal-lysosomal degradation and delivery. This role leads both clinical pharmacology and nonclinical sciences, integrating PK/PD, exposure-response and dose-selection strategy with translational science and toxicology strategy across the pipeline.
A successful candidate can effectively work cross-functionally and has a strong drug development track record of advancing programs from target discovery through IND/clinical stage.